Replimune Group, Inc. Form 8-K Summary
Reporting date: September 19, 2023. The filing reports the appointment of Emily Hill as Chief Financial Officer, effective September 18, 2023. It does not report quarterly or annual operating results.
Business Context and Executive Appointment
- Replimune is a Delaware biotechnology company headquartered in Woburn, Massachusetts, with common stock listed on Nasdaq under the symbol REPL.
- Emily Hill, age 43, was appointed Chief Financial Officer. She previously served as CFO of PTC Therapeutics, Inc. since June 2019 and held prior investor-relations and equity-research roles.
- The company stated that there are no reportable family relationships or material related-party transactions involving Ms. Hill.
Compensation and Equity Awards
- Annual base salary: $495,000.
- Target annual discretionary bonus: 40% of annualized base salary, subject to individual and corporate performance goals.
- Stock option: 125,000 shares at an exercise price of $18.00 per share, vesting over four years. Twenty-five percent vests on the first anniversary, with the remainder vesting monthly over the following three years.
- Restricted stock units: 83,330 shares, vesting over four years. Twenty-five percent vests on August 15, 2024, with the remainder vesting in three annual installments.
- The equity awards were granted outside the 2018 Omnibus Incentive Compensation Plan but are subject to consistent terms and conditions.
Severance, Change-of-Control and Other Terms
- If terminated without Cause or if Ms. Hill resigns for Good Reason, subject to an effective release, she may receive 12 months of base salary continuation and reimbursement of eligible COBRA premiums for up to 12 months, subject to specified termination conditions.
- If termination occurs without Cause or for Good Reason within one year after a Change of Control, she may receive 12 months of base salary plus the target annual bonus for the termination year, together with eligible COBRA reimbursements.
- The agreement includes customary Section 280G tax provisions, non-competition and non-solicitation covenants, and confidentiality restrictions.
Financial Metrics, Guidance and Risks
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash-balance, operating guidance or other financial performance metrics. It does not announce a change to business outlook or disclose new litigation, contingencies or unusual operating items. The primary investor-relevant financial impact is the ongoing cash compensation, potential severance obligations and dilution associated with the equity awards.
Material Changes Versus Prior Comparable Period
The filing does not present a prior-period comparison. The material change disclosed is the replacement or appointment of the company’s Chief Financial Officer, effective September 18, 2023.
Important Facts for Investors to Verify
- Confirm the identity and effective date of the new Chief Financial Officer.
- Review the full employment agreement, which the company stated it intended to file with its Form 10-Q for the quarter ended September 30, 2023.
- Assess the potential dilution from the 125,000 stock options and 83,330 restricted stock units.
- Evaluate the cash cost of the $495,000 base salary, target bonus opportunity and any future severance or COBRA obligations.
- Review subsequent filings for the company’s liquidity, financing needs, operating results and any changes in executive compensation.